a. culturing first and second human skin samples for about 3 days to about 19 days, wherein the first and second human skin samples each comprise an epidermal layer and a dermal layer and are obtained from human donor tissue;
b. contacting the first human skin sample with at least one test agent;
c. contacting the second human skin sample with a positive control;
d. generating a transcriptional profile from the first and second human skin samples of a set of genes consisting of fibrillin 1 (FBN1), fibulin 1 (FBLN1), tenascin XB (TNXB), fibronectin 1 (FN1), lysyl oxidase homolog 2 (LOXL2), collagen, type I, alpha 1 (COL1A1), collagen, type III, alpha 1 (COL3A1), elastin (ELN) and lysyl oxidase-like 1 (LOXL1);
e. determining a change in the direction of regulation of FBN1, FBLN1, TNXB, FN1, LOXL2, COLIA1, COL3A1, ELN and LOXL1 for the first and second human skin samples based on the transcriptional profiles of (d); and
f. identifying the test agent as effective for providing an anti-aging skin benefit when the change in direction of regulation of the genes in (e) is the same for the first and second skin samples.